Determination of COVID-19 Related Virus in Central Nervous System

San Donato Group (GSD)

Status

Enrolling

Conditions

COVID-19 Testing

CNS Disease

CNS Infection

Treatments

Diagnostic Test: Determination of SARS-CoV2 presence in CNS

Study type

Observational

Funder types

Other

Identifiers

NCT04775784

NCH08-2020

Details and patient eligibility

About

Coronavirus disease 2019 (COVID-19) is a highly infectious pandemic disease caused by SARS-CoV-2 virus. Central Nervous System (CNS) complications associated with COVID-19 might be secondary sequelae due to exuberant systemic innate-mediated hyper-inflammation, which may impair neurovascular endothelial function, disrupt blood brain barrier (BBB), activates CNS innate immune signaling pathways, and induces parainfectious autoimmunity, potentially contributing to the CNS manifestations. Although the predominant clinical manifestation of SARS-CoV-2 is characterized by dyspnea, unremitting fever and hypoxemic respiratory failure, neurologic manifestations do occur in most hospitalized SARS-CoV-2 patients and include non-specific encephalopathy, psychosis, meningitis/encephalitis, myelitis, cerebrovascular events, Guillain-Barre' syndrome, and cranial or peripheral neuropathies, such as anosmia and ageusia. To date, data about primary CNS involvement due to neurotropism and direct neuroinvasion are still lacking.

Full description

Determination of SARS-CoV-2 presence in central nervous system

Enrollment

300 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adult patients
Patients candidate for CNS surgery
Patients who have been tested for nasopharyngeal swab for SARS-CoV-2
Patients who have been tested for serology test for anti SARS-CoV-2 immunoglobulinG (IgG) and immunoglobulinM (IgM) antibodies
Patients able to sign informed consent

Exclusion criteria